U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H8O6S4.2Na
Molecular Weight 326.342
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIMESNA

SMILES

[Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O

InChI

InChIKey=KQYGMURBTJPBPQ-UHFFFAOYSA-L
InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H8O6S4
Molecular Weight 280.363
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Dimesna is a prodrug of mesna (dimer of mesna). Dimesna is reduced to mesna in the kidneys. Dimesna does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in the renal tubular cell line LLC-PK1. Dimesna is a mucolytic agent used to alleviate toxic side effects of antitumor drugs. The organic acid transporter OAT4 on the luminal side of the proximal renal tubule facilitates the reabsorption of dimesna, and therefore its reduction to mesna, whereas the multidrug and toxin extrusion protein MATE1, the multidrug resistance protein MRP2, and P glycoprotein facilitate the efflux of mesna and/or dimesna back into the lumen; dimesna may also be excreted unchanged by MRP4. It has therefore been suggested that polymorphism of these renal transport proteins or transporter-mediated drug-drug interactions may reduce the efficacy of mesna and dimesna.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
2010-09
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
2010-04
Efficient, chemoselective synthesis of immunomicelles using single-domain antibodies with a C-terminal thioester.
2009-07-20
Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
2009-04-01
One-step refolding and purification of disulfide-containing proteins with a C-terminal MESNA thioester.
2008-10-01
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
2008-10
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
2005-05-09
Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
2004-08-01
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
2004-04-19
The effect of cytoprotective agents in platinum anticancer therapy.
2004
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
2003-08
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
2003-06
Vibrational spectroscopic studies of mesna and dimesna.
2003-06
The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
2003-06
Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
2003-05
Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
2003-05
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
2002-05
Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.
1983-09
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
1983-02-15
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
1982
Patents

Patents

Substance Class Chemical
Created
by admin
on Mon Mar 31 17:58:04 GMT 2025
Edited
by admin
on Mon Mar 31 17:58:04 GMT 2025
Record UNII
230R951Y4D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIMESNA
INN   MART.   MI  
INN   USAN  
Official Name English
NSC-716976
Preferred Name English
dimesna [INN]
Common Name English
Disodium 2,2?-dithiodiethanesulfonate
Systematic Name English
DIMESNA [MI]
Common Name English
TAVOCEPT
Brand Name English
Ethanesulfonic acid, 2,2?-dithiobis-, sodium salt (1:2)
Systematic Name English
NSC-760345
Code English
BNP-7787
Code English
DISODIUM 2,2'-DITHIODIETHANESULPHONATE
Systematic Name English
DIMESNA [MART.]
Common Name English
BNP7787
Code English
Dimesna [WHO-DD]
Common Name English
DIMESNA [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2082
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
Code System Code Type Description
EVMPD
SUB07166MIG
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
FDA UNII
230R951Y4D
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
NSC
716976
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
CAS
16208-51-8
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
ChEMBL
CHEMBL2009034
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
SMS_ID
100000082639
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
USAN
NN-30
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
MESH
C027032
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
NSC
760345
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
MERCK INDEX
m4503
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C1365
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
ECHA (EC/EINECS)
240-337-2
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
INN
4888
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
EPA CompTox
DTXSID6066024
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
PUBCHEM
65625
Created by admin on Mon Mar 31 17:58:04 GMT 2025 , Edited by admin on Mon Mar 31 17:58:04 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE